The market for biotech initial public offerings has rebounded this year, spurred by generalist investors who previously shunned the industry, but the party won't last long, Luke Timmerman writes. Neglected diseases will get a boost, as will regional innovation hubs, and small companies will gain negotiating leverage, but some investors will lose interest after they lose money, Timmerman writes.

Full Story:

Related Summaries